These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33331635)

  • 1. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19.
    Kao SW; Liu ZH; Wu TS; Ku SW; Tsai CL; Shie SS; Huang PY; Wu YM; Hsiao YH; Chen NY
    J Antimicrob Chemother; 2021 Feb; 76(3):722-728. PubMed ID: 33331635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China.
    Liu J; Li C; Sun Y; Fu C; Wei S; Zhang X; Ma J; Zhao Q; Huo Y
    Sci Rep; 2024 May; 14(1):10620. PubMed ID: 38724547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana.
    Bareng OT; Moyo S; Zahralban-Steele M; Maruapula D; Ditlhako T; Mokaleng B; Mokgethi P; Choga WT; Moraka NO; Pretorius-Holme M; Mine MO; Raizes E; Molebatsi K; Motswaledi MS; Gobe I; Mohammed T; Gaolathe T; Shapiro R; Mmalane M; Makhema JM; Lockman S; Essex M; Novitsky V; Gaseitsiwe S
    J Antimicrob Chemother; 2022 Apr; 77(5):1385-1395. PubMed ID: 35229102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
    Vardhanabhuti S; Taiwo B; Kuritzkes DR; Eron JJ; Bosch RJ
    Antivir Ther; 2015; 20(1):73-6. PubMed ID: 24699164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study).
    Vandenhende MA; Perrier A; Bonnet F; Lazaro E; Cazanave C; Reigadas S; Chêne G; Morlat P;
    Antivir Ther; 2015; 20(6):655-60. PubMed ID: 25735799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing low-level HIV viraemia in antiretroviral therapy: a systematic review and meta-analysis.
    Zaçe D; Rindi LV; Compagno M; Colagrossi L; Santoro MM; Andreoni M; Perno CF; Sarmati L;
    Sex Transm Infect; 2024 Oct; 100(7):460-468. PubMed ID: 39288983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database.
    Han WM; Broom J; Bopage R; Templeton DJ; Edmiston N; Petoumenos K;
    Trop Med Int Health; 2024 Jan; 29(1):42-56. PubMed ID: 38009461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia.
    Djiyou ABD; Penda CI; Madec Y; Ngondi GD; Moukoko A; Eboumbou CE; Aghokeng AF
    J Antimicrob Chemother; 2023 Dec; 78(12):2938-2942. PubMed ID: 37921335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
    Delaugerre C; Gallien S; Flandre P; Mathez D; Amarsy R; Ferret S; Timsit J; Molina JM; de Truchis P
    PLoS One; 2012; 7(5):e36673. PubMed ID: 22590588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 low-level viraemia predicts virological failure in first-line and second-line ART-experienced individuals in India: A retrospective longitudinal study.
    Dinesha TR; Boobalan J; Kumar CV; Manikandan P; Muhila M; Solomon SS; Srikrishnan AK; Murugavel KG
    HIV Med; 2024 Jul; 25(7):852-861. PubMed ID: 38663865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy.
    Gaifer Z; Boulassel MR
    J Int Assoc Provid AIDS Care; 2020; 19():2325958220979817. PubMed ID: 33372823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.
    Palich R; Wirden M; Peytavin G; Lê MP; Seang S; Abdi B; Schneider L; Tubiana R; Valantin MA; Paccoud O; Soulié C; Calvez V; Katlama C; Marcelin AG
    J Antimicrob Chemother; 2020 Oct; 75(10):2981-2985. PubMed ID: 32642769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
    Bai R; Lv S; Hua W; Su B; Wang S; Shao Y; Li Z; Liu A; Sun L; Dai L
    HIV Med; 2022 Mar; 23 Suppl 1():72-83. PubMed ID: 35293102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis.
    Taramasso L; Magnasco L; Bruzzone B; Caligiuri P; Bozzi G; Mora S; Balletto E; Tatarelli P; Giacomini M; Di Biagio A
    J Clin Virol; 2020 Feb; 123():104255. PubMed ID: 31927152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-level HIV viraemia during antiretroviral therapy: Longitudinal patterns and predictors of viral suppression.
    Elén S; Björkman P; Zazzi M; Böhm M; Bernal E; Sönnerborg A; Elvstam O;
    HIV Med; 2024 Jan; 25(1):107-116. PubMed ID: 37721192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
    Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
    HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.
    Wirden M; Todesco E; Valantin MA; Lambert-Niclot S; Simon A; Calin R; Tubiana R; Peytavin G; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2015 Aug; 70(8):2347-53. PubMed ID: 25921516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort.
    Zhang T; Ding H; An M; Wang X; Tian W; Zhao B; Han X
    BMC Infect Dis; 2020 Feb; 20(1):147. PubMed ID: 32066392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.
    Gonzalez-Serna A; Min JE; Woods C; Chan D; Lima VD; Montaner JS; Harrigan PR; Swenson LC
    Clin Infect Dis; 2014 Apr; 58(8):1165-73. PubMed ID: 24429436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa.
    Bangalee A; Hans L; Steegen K
    J Antimicrob Chemother; 2021 Sep; 76(10):2659-2665. PubMed ID: 34278422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.